Safety Trial of Naproxen Sodium/ Diphenhydramine (MUST)

This study has been completed.
Information provided by (Responsible Party):
Bayer Identifier:
First received: May 17, 2011
Last updated: May 13, 2015
Last verified: May 2015
The purpose of this trial is to see how safe the combination of naproxen sodium 440 mg and diphenhydramine hydrochloride (DPH) 50 mg (the investigational product) is compared to placebo (capsules containing no drug) when taken for 10 days.

Condition Intervention Phase
Drug: Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Official Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Safety and Tolerability Trial of Naproxen Sodium/ Diphenhydramine Combination in an OTC Population

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Percentage of Subjects With Any Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product [ Time Frame: 10 days after randomization ] [ Designated as safety issue: Yes ]
    Please see further details in Adverse Events (AE) section

  • Percentage of Subjects With Any Serious Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product [ Time Frame: 10 days after randomization ] [ Designated as safety issue: Yes ]
    Please see further details in AE section

Other Outcome Measures:
  • Percentage of Subjects Who Discontinued Due to an Adverse Event for Those Subjects Who Are Randomized and Take at Least One Dose of Investigational Product [ Time Frame: 10 days after randomization ] [ Designated as safety issue: Yes ]
  • Treatment Compliance - Number of Capsules Taken [ Time Frame: 10 days after randomization ] [ Designated as safety issue: No ]
  • Treatment Compliance - Duration of Exposure to Treatment in Days [ Time Frame: 10 days after randomization ] [ Designated as safety issue: No ]

Enrollment: 326
Study Start Date: May 2011
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111) Drug: Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)
2 capsules each containing naproxen sodium 220 mg /diphenhydramine hydrochloride (DPH) 25 mg are taken orally with a full glass of water approximately 30 minutes prior to bedtime for 10 consecutive days
Placebo Comparator: Placebo Drug: Placebo
2 placebo capsules are taken orally with a full glass of water 30 minutes prior to bedtime for 10 consecutive days


Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy, ambulatory, male and female volunteers ages 12 and older
  • History of experiencing occasional sleeplessness accompanied by aches and pains at least two times, but not continually for more than 14 days per month, in at least 2 of the past 3 months
  • Female subjects of childbearing potential must be using a medically acceptable form of birth control, e.g., oral or patch contraceptives, intrauterine device, Depo-Provera®, for at least 1 month prior to screening (3 months on oral contraceptives), or double-barrier and have a negative pregnancy test at Screening. Female subjects of nonchildbearing potential must be amenorrheic for at least 2 years or have had a hysterectomy and/or bilateral oophorectomy
  • Be willing and able to participate in all scheduled visits, treatment plan, tests and other trial procedures according to the protocol
  • Provide a personally signed and dated informed consent indicating that the subject has been informed of all pertinent aspects of the trial, (subjects <18 years of age must sign a written assent and have parental or guardian consent).

Exclusion Criteria:

  • History of hypersensitivity to naproxen sodium, acetaminophen, or any NSAIDs (Nonsteroidal Antiinflammatory Drugs), diphenhydramine or any other antihistamines, and similar pharmacological agents or components of the product
  • Evidence or history of clinically significant (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or malignancies with the last 5 years
  • A history of a chronic or severe sleep problem which does not respond to OTC (Over-the-counter) medication and/or requires a prescription hypnotic or sedative
  • Currently experiencing chronic pain or on chronic NSAID therapy (defined as taking a daily [5 to 7 days per week] regimen of prescription or OTC NSAIDs)
  • Current or past history of gastrointestinal ulcers or bleeding or other bleeding disorders
  • Use of any OTC or prescription medications with which the administration of naproxen, acetaminophen, or any NSAIDs, diphenhydramine or any other antihistamines or sedatives, is contraindicated
  • Chronic use of other products containing diphenhydramine, including topical products
  • Use of steroids or blood thinning (anticoagulant) drugs (aspirin 81 mg is permitted if the dose has been taken for at least one month prior to screening)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01365052

United States, Arizona
Chandler, Arizona, United States, 85224
Mesa, Arizona, United States, 85203
Peoria, Arizona, United States, 85381
United States, California
Anaheim, California, United States, 92801
Rancho Cucamonga, California, United States, 91730
Sacramento, California, United States, 95816
United States, Colorado
Colorado Springs, Colorado, United States, 80922
United States, Florida
Kissimmee, Florida, United States, 34741
Pembroke Pines, Florida, United States, 33028
South Miami, Florida, United States, 33143
United States, Georgia
Stockbridge, Georgia, United States, 30281
United States, Louisiana
Metairie, Louisiana, United States, 70006
United States, Maryland
Elkridge, Maryland, United States, 21075
United States, Rhode Island
Warwick, Rhode Island, United States, 02886
United States, South Carolina
Mt. Pleasant, South Carolina, United States, 29464
United States, Texas
Fort Worth, Texas, United States, 76135
San Angelo, Texas, United States, 76904
San Antonio, Texas, United States, 78231
United States, Utah
Salt Lake City, Utah, United States, 84106
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer Identifier: NCT01365052     History of Changes
Other Study ID Numbers: 15560 
Study First Received: May 17, 2011
Results First Received: January 24, 2014
Last Updated: May 13, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Bayer:
Maximum Use Safety Trial

Additional relevant MeSH terms:
Analgesics, Non-Narcotic
Anesthetics, Local
Anti-Allergic Agents
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Autonomic Agents
Central Nervous System Depressants
Cyclooxygenase Inhibitors
Dermatologic Agents
Enzyme Inhibitors
Gastrointestinal Agents
Gout Suppressants
Histamine Agents
Histamine Antagonists
Histamine H1 Antagonists
Hypnotics and Sedatives
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Sensory System Agents processed this record on May 25, 2016